Argent BioPharma Limited (RGTLF)
OTCMKTS
· Delayed Price · Currency is USD
0.1110
-0.0391 (-26.05%)
At close: May 22, 2025
Argent BioPharma Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2015 - 2019 |
| Revenue | 0.3 | 0.89 | 3.39 | 4.73 | 3 | 2.08 | Upgrade
|
| Revenue Growth (YoY) | -77.66% | -73.69% | -28.41% | 57.94% | 44.10% | 216.83% | Upgrade
|
| Cost of Revenue | 0.67 | 1.2 | 2.04 | 4.17 | 1.9 | 1.9 | Upgrade
|
| Gross Profit | -0.38 | -0.3 | 1.35 | 0.56 | 1.1 | 0.17 | Upgrade
|
| Selling, General & Admin | 17.3 | 15.56 | 13.34 | 11.83 | 7.79 | 6.61 | Upgrade
|
| Research & Development | 1.82 | 2.32 | 2.99 | - | - | - | Upgrade
|
| Other Operating Expenses | 0.32 | -0.16 | 0.22 | 4.23 | 5.25 | 4.85 | Upgrade
|
| Operating Expenses | 19.46 | 17.74 | 16.56 | 16.06 | 13.04 | 11.46 | Upgrade
|
| Operating Income | -19.84 | -18.04 | -15.21 | -15.5 | -11.94 | -11.29 | Upgrade
|
| Interest Expense | -0.05 | -0.48 | -0.26 | -0.21 | -0.37 | -0.14 | Upgrade
|
| Interest & Investment Income | 0 | 0 | 0 | 0 | 0.01 | 0.01 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.83 | 0.83 | -1.22 | 0.08 | -0.03 | -0.15 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.42 | 0.06 | 0.09 | -1.24 | -3.57 | -2.09 | Upgrade
|
| EBT Excluding Unusual Items | -18.63 | -17.63 | -16.6 | -16.86 | -15.9 | -13.65 | Upgrade
|
| Merger & Restructuring Charges | -1.36 | - | - | - | - | - | Upgrade
|
| Impairment of Goodwill | - | - | -3.15 | -3.9 | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | -1.37 | 1.34 | -1.39 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -1.26 | -1.26 | - | - | - | - | Upgrade
|
| Asset Writedown | - | - | - | - | - | -5.12 | Upgrade
|
| Pretax Income | -22.62 | -17.55 | -21.13 | -20.77 | -15.9 | -18.77 | Upgrade
|
| Income Tax Expense | - | - | 0 | - | -0.03 | - | Upgrade
|
| Earnings From Continuing Operations | -22.62 | -17.55 | -21.13 | -20.77 | -15.87 | -18.77 | Upgrade
|
| Earnings From Discontinued Operations | - | - | - | - | - | -0.6 | Upgrade
|
| Net Income to Company | -22.62 | -17.55 | -21.13 | -20.77 | -15.87 | -19.37 | Upgrade
|
| Minority Interest in Earnings | 0 | 0.02 | 0.31 | 0.42 | 0 | 0.01 | Upgrade
|
| Net Income | -22.62 | -17.53 | -20.82 | -20.35 | -15.87 | -19.36 | Upgrade
|
| Net Income to Common | -22.62 | -17.53 | -20.82 | -20.35 | -15.87 | -19.36 | Upgrade
|
| Shares Outstanding (Basic) | 51 | 37 | 3 | 3 | 2 | 1 | Upgrade
|
| Shares Outstanding (Diluted) | 51 | 37 | 3 | 3 | 2 | 1 | Upgrade
|
| Shares Change (YoY) | 284.88% | 1155.86% | 14.85% | 34.63% | 37.91% | 14.31% | Upgrade
|
| EPS (Basic) | -0.45 | -0.47 | -7.07 | -7.93 | -8.33 | -14.01 | Upgrade
|
| EPS (Diluted) | -0.45 | -0.47 | -7.10 | -7.93 | -8.33 | -14.03 | Upgrade
|
| Free Cash Flow | -11.16 | -14.8 | -12.18 | -14.85 | -15.32 | -10.92 | Upgrade
|
| Free Cash Flow Per Share | -0.22 | -0.40 | -4.13 | -5.79 | -8.04 | -7.90 | Upgrade
|
| Gross Margin | -127.08% | -34.13% | 39.88% | 11.89% | 36.70% | 8.40% | Upgrade
|
| Operating Margin | -6705.93% | -2024.69% | -448.91% | -327.54% | -398.48% | -542.80% | Upgrade
|
| Profit Margin | -7644.88% | -1967.34% | -614.71% | -430.00% | -529.70% | -931.29% | Upgrade
|
| Free Cash Flow Margin | -3771.39% | -1661.19% | -359.40% | -313.85% | -511.23% | -525.16% | Upgrade
|
| EBITDA | -18.81 | -16.97 | -14.67 | -15.4 | -11.6 | -10.96 | Upgrade
|
| D&A For EBITDA | 1.03 | 1.08 | 0.54 | 0.1 | 0.34 | 0.32 | Upgrade
|
| EBIT | -19.84 | -18.04 | -15.21 | -15.5 | -11.94 | -11.29 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.